SLC16A1 and breast carcinoma: In breast cancer, high expression of MCT1 is associated with the triple-negative [16] and basal-like phenotype [17], elevated glycolysis [18, 19], and poor outcome in TNBC patients [16], making it of great interest as a therapeutic target.